Metered-dose aerosolized bronchodilators in prehospital care: A feasibility study

James Hawkins; Kirsten Hakala; Michael B. Heller; Richard M. Kaplan; Sandra Schneider; Ronald D. Stewart

doi:10.1016/0736-4679(86)90001-6

Metered-dose aerosolized bronchodilators in prehospital care: A feasibility study

James Hawkins, Kirsten Hakala, Michael B. Heller, Richard M. Kaplan, Sandra Schneider, Ronald D. Stewart

Résultat de recherche: Article › examen par les pairs

4 Citations (Scopus)

Résumé

The prehospital use of aerosolized bronchodilators was studied in 50 adult patients with bronchospasm. The specific β₂-agonist, albuterol, was discharged from a metered-dose inhaler (MDI) into the Inhal-aid® reservoir-delivery device. No serious adverse effects were encountered, although a substantial proportion of the patients (36%) had difficulty utilizing the device. Ability to use the system properly correlated with improvement in symptoms; inability to use the device was most clearly related to severity of clinical presentation. It is concluded that the use of aerosolized bronchodilators is feasible in prehospital care and most useful in patients with mild or moderately severe symptoms.

Langue d'origine	English
Pages (de-à)	273-277
Nombre de pages	5
Journal	Journal of Emergency Medicine
Volume	4
Numéro de publication	4
DOI	https://doi.org/10.1016/0736-4679(86)90001-6
Statut de publication	Published - 1986
Publié à l'externe	Oui

ASJC Scopus Subject Areas

Emergency Medicine

Accès au document

10.1016/0736-4679(86)90001-6

Autres fichiers et liens

Citer

@article{3b09d9f59f4f414e82d3de3a8b5d0437,

title = "Metered-dose aerosolized bronchodilators in prehospital care: A feasibility study",

abstract = "The prehospital use of aerosolized bronchodilators was studied in 50 adult patients with bronchospasm. The specific β2-agonist, albuterol, was discharged from a metered-dose inhaler (MDI) into the Inhal-aid{\textregistered} reservoir-delivery device. No serious adverse effects were encountered, although a substantial proportion of the patients (36%) had difficulty utilizing the device. Ability to use the system properly correlated with improvement in symptoms; inability to use the device was most clearly related to severity of clinical presentation. It is concluded that the use of aerosolized bronchodilators is feasible in prehospital care and most useful in patients with mild or moderately severe symptoms.",

author = "James Hawkins and Kirsten Hakala and Heller, {Michael B.} and Kaplan, {Richard M.} and Sandra Schneider and Stewart, {Ronald D.}",

year = "1986",

doi = "10.1016/0736-4679(86)90001-6",

language = "English",

volume = "4",

pages = "273--277",

journal = "Journal of Emergency Medicine",

issn = "0736-4679",

publisher = "Elsevier USA",

number = "4",

}

TY - JOUR

T1 - Metered-dose aerosolized bronchodilators in prehospital care

T2 - A feasibility study

AU - Hawkins, James

AU - Hakala, Kirsten

AU - Heller, Michael B.

AU - Kaplan, Richard M.

AU - Schneider, Sandra

AU - Stewart, Ronald D.

PY - 1986

Y1 - 1986

N2 - The prehospital use of aerosolized bronchodilators was studied in 50 adult patients with bronchospasm. The specific β2-agonist, albuterol, was discharged from a metered-dose inhaler (MDI) into the Inhal-aid® reservoir-delivery device. No serious adverse effects were encountered, although a substantial proportion of the patients (36%) had difficulty utilizing the device. Ability to use the system properly correlated with improvement in symptoms; inability to use the device was most clearly related to severity of clinical presentation. It is concluded that the use of aerosolized bronchodilators is feasible in prehospital care and most useful in patients with mild or moderately severe symptoms.

AB - The prehospital use of aerosolized bronchodilators was studied in 50 adult patients with bronchospasm. The specific β2-agonist, albuterol, was discharged from a metered-dose inhaler (MDI) into the Inhal-aid® reservoir-delivery device. No serious adverse effects were encountered, although a substantial proportion of the patients (36%) had difficulty utilizing the device. Ability to use the system properly correlated with improvement in symptoms; inability to use the device was most clearly related to severity of clinical presentation. It is concluded that the use of aerosolized bronchodilators is feasible in prehospital care and most useful in patients with mild or moderately severe symptoms.

UR - http://www.scopus.com/inward/record.url?scp=0022974501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022974501&partnerID=8YFLogxK

U2 - 10.1016/0736-4679(86)90001-6

DO - 10.1016/0736-4679(86)90001-6

M3 - Article

C2 - 3540093

AN - SCOPUS:0022974501

SN - 0736-4679

VL - 4

SP - 273

EP - 277

JO - Journal of Emergency Medicine

JF - Journal of Emergency Medicine

IS - 4

ER -

Metered-dose aerosolized bronchodilators in prehospital care: A feasibility study

Résumé

ASJC Scopus Subject Areas

Accès au document

Autres fichiers et liens

Empreinte numérique

Citer